An observational study in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 27 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-16.
Sponsored by Eli Lilly and Company · Observational
The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch. The additional goals are: 1)to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient quality of life, 3) to assess the impact of switch from or to the rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate the total costs (direct and indirect) associated with switching, in either direction between rapid-acting analog and short-acting human insulin within the first year following the switch.
9,357 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 2,459 is above the median of 300 across 1,588 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with Type II Diabetes treated with a regimen which includes any rapid-acting analog insulin or any short-acting human insulin
Exclusion Criteria:
Patients on rapid-acting analog insulins who switch to short-acting human insulin
Drug: Analog or Human Insulin
Patients on short-acting human insulins who switch to rapid-acting analog insulin
Drug: Analog or Human Insulin
prescribed in accordance with usual clinical practice
The estimation of the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and a short-acting human insulin therapy within the first year following the switch.
Time frame: 1 year
Change in Euro Quality of Life (EQ-5D)
Time frame: 1 year
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time frame: 1 year
Change in Diabetes Health Profile (DHP-18)
Time frame: 1 year
The estimation of the total costs (direct and indirect) associated with switching, in either direction, between rapid-acting analog and short-acting human insulin within the first year following the switch
Time frame: 1 year
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company